Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80638
Name B-cell acute lymphoblastic leukemia
Definition An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS G13D Everolimus B-cell acute lymphoblastic leukemia no benefit detail...
KMT2A rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK1 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK1 mutant N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK2 mutant N/A B-cell acute lymphoblastic leukemia not applicable detail...
JAK3 mutant N/A B-cell acute lymphoblastic leukemia not applicable detail...
ABL1 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
FGFR1 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
FLT3 rearrange N/A B-cell acute lymphoblastic leukemia not applicable detail...
CDKN2A H142R Palbociclib B-cell acute lymphoblastic leukemia sensitive detail...
TP53 mutant N/A B-cell acute lymphoblastic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00450944 Phase I Combotox Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia Completed USA 0
NCT01087294 Phase I Anti-CD19 CAR-T cells Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT01853631 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) Recruiting USA 0
NCT02143414 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dasatinib + Prednisone Blinatumomab + Dasatinib Blinatumomab Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT02311998 Phase Ib/II Bosutinib + Inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Completed USA 0
NCT02315612 Phase I Anti-CD22 CAR T cells Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Active, not recruiting USA 0
NCT02420717 Phase II Ruxolitinib Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Terminated USA 0
NCT02435849 Phase II Tisagenlecleucel Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT02458014 Phase II Blinatumomab Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Active, not recruiting USA 0
NCT02535806 Phase II Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults Terminated USA 0
NCT02650414 Phase I Anti-CD22 CAR T cells CD22 Redirected Autologous T Cells for ALL Recruiting USA 0
NCT02730312 Phase I Vibecotamab PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Completed USA 0
NCT02828358 Phase II Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Active, not recruiting USA | CAN | AUS 1
NCT02881086 Phase III Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Active, not recruiting DEU 0
NCT03016377 Phase Ib/II Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Recruiting USA 0
NCT03114865 Phase Ib/II Blinatumomab + Dexamethasone A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Active, not recruiting USA 0
NCT03123939 Phase III Tisagenlecleucel Phase III B in Acute Lymphoblastic Leukemia Completed ITA | FRA | ESP | DEU | CAN | BEL | AUT 2
NCT03233854 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells NKTR-255 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT03441061 Phase II Inotuzumab ozogamicin Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Recruiting USA 0
NCT03448393 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT03590171 Phase II Bortezomib International Study for Treatment of High Risk Childhood Relapsed ALL 2010 Recruiting ITA | GBR | FRA | BEL | AUT | AUS 9
NCT03594955 Phase Ib/II SAR440234 First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Terminated USA | FRA 0
NCT03595917 Phase I Asciminib + Blinatumomab + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Recruiting USA 0
NCT03620058 Phase I CART22-65s cells + huCART19 CART22-65s cells CART22 Alone or in Combination With huCART19 for ALL Active, not recruiting USA 0
NCT03677596 FDA approved Inotuzumab ozogamicin A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Completed USA | ESP 6
NCT03743246 Phase Ib/II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Recruiting USA | ITA | FRA | ESP | DEU 1
NCT03792633 Phase II huCART19 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Active, not recruiting USA 0
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT03876769 Phase II Tisagenlecleucel Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 5
NCT04029038 Phase Ib/II CD19/CD22 CAR T cells Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Withdrawn USA 0
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN 1
NCT04049383 Phase I Anti-CD19-CD20 CAR T cells CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T) Recruiting USA 0
NCT04094311 Phase III Tisagenlecleucel Study of Out of Specification for Tisagenlecleucel Recruiting CAN 1
NCT04150497 Phase I UCART22 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) Recruiting USA | FRA 0
NCT04214886 Phase I CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT04307576 Phase III Imatinib Blinatumomab Inotuzumab ozogamicin A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting GBR | FRA | DEU | BEL 10
NCT04506086 FDA approved Blinatumomab Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) Recruiting USA 0
NCT04509700 Phase II Parsaclisib Itacitinib + Parsaclisib Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Recruiting USA | ITA | GBR | FRA | ESP | BEL | AUT 10
NCT04512716 Phase I Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT04521231 Phase I Blinatumomab A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 3
NCT04530565 Phase III Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Dasatinib Ponatinib Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Ponatinib + Prednisone Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Mesna + Methotrexate + Vincristine Sulfate Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ponatinib + Vincristine Sulfate Dasatinib + Prednisone Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Recruiting USA 2
NCT04546399 Phase II Blinatumomab + Methotrexate + Nivolumab Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Leucovorin + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Leucovorin + Methotrexate + Nivolumab Blinatumomab + Dexamethasone + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate + Nivolumab Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate + Nivolumab Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Suspended USA | CAN | AUS 1
NCT04556084 Phase II Blinatumomab Blinatumomab Bridging Therapy Recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Active, not recruiting USA 0
NCT04690595 Phase I BAFFR-CAR T cells BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL Recruiting USA 0
NCT04746209 Phase II Blinatumomab Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT Recruiting USA 0
NCT04747912 Phase II Dasatinib + Dexamethasone + Inotuzumab ozogamicin + Methotrexate Dasatinib + Dexamethasone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Dasatinib + Inotuzumab ozogamicin + Methotrexate Dexamethasone + Inotuzumab ozogamicin + Methotrexate + Ponatinib + Vincristine Sulfate Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) Recruiting USA 0
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04785547 Phase II Blinatumomab ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT Terminated ITA | FRA | ESP | BEL | AUT 5
NCT04845035 Phase II Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Ponatinib Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Asparaginase + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate + Ponatinib Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT04872790 Phase I Dasatinib + Methotrexate + Prednisone + Rituximab + Venetoclax Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Recruiting USA 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT04994717 Phase III Blinatumomab Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT05016947 Phase I Dexamethasone + Inotuzumab ozogamicin + Venetoclax Venetoclax Plus Inotuzumab for B-ALL Recruiting USA 0
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05032183 Phase Ib/II Cytarabine + Filgrastim + Methotrexate + Rituximab + Tagraxofusp-erzs Cyclophosphamide + Dexamethasone + Mesna + Methotrexate + Rituximab + Tagraxofusp-erzs + Vincristine Sulfate Tagraxofusp-erzs Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting USA 0
NCT05049473 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Hydrocortisone + Ifosfamide + Methotrexate + Prednisone + Rituximab + Vincristine Sulfate + Vindesine Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. Unknown status ESP 0
NCT05157971 Phase I Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Pegaspargase + Prednisone + Venetoclax + Vincristine Sulfate Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT05182385 Phase Ib/II Blinatumomab + Venetoclax Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Recruiting DEU 0
NCT05292664 Phase I Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies Recruiting USA 0
NCT05303792 Phase II Cytarabine + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Mesna + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Mesna + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Mesna + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate + Methylprednisolone + Rituximab Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Inotuzumab ozogamicin + Methotrexate + Methylprednisolone + Rituximab Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma Recruiting USA 0
NCT05310591 Phase Ib/II Cyclophosphamide + Fludarabine Nivolumab Tisagenlecleucel Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence (CAPTiRALL) Recruiting FRA 0
NCT05348889 Phase Ib/II 1A46 First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies Recruiting USA 0
NCT05362773 Phase I MGD024 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT05366218 Phase Ib/II Tafasitamab-cxix Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL) Recruiting DEU 0
NCT05442515 Phase Ib/II CD19/CD22 CAR T cells Cyclophosphamide + Fludarabine CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting USA 0
NCT05453500 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Tafasitamab-cxix + Vincristine Sulfate Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Recruiting USA 0
NCT05460533 Phase II Tisagenlecleucel A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Recruiting USA 0
NCT05535855 Phase I UCD19 CAR T cells UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 Recruiting USA 0
NCT05581030 Phase I Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Sulfate Cytarabine + Methotrexate Calaspargase pegol-mknl + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Recruiting USA 0
NCT05645718 Phase II Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Pegfilgrastim + Prednisone + Rituximab + Vincristine Sulfate Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Recruiting USA 0
NCT05674175 Phase Ib/II CART22-65s cells + huCART19 Co-administration of CART22-65s and huCART19 for B-ALL Recruiting USA 0
NCT05779930 Phase I Anti-CD19 CAR-T cells Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL Not yet recruiting USA 0
NCT05848687 Phase Ib/II Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Recruiting USA 0
NCT05961696 Phase I Mosunetuzumab-axgb A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT05993949 Phase I Dasatinib Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia Recruiting USA 0
NCT06034275 Phase I VIP943 Study of VIP943 in Subjects With Advanced CD123 pos Hematologic Malignancies Recruiting USA 0
NCT06137118 Phase Ib/II TNB-486 AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT06144606 Phase II Brexucabtagene autoleucel Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting USA 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting GBR 0
NCT06287528 Phase I 19-28z/IL-18 CAR-T cells A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) Recruiting USA 0